Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q3 2019 · 10-Q
Revenue—
Net Income-$7.22M-$7.22MN/M vs Q3 2018 EPS Diluted-$0.24-$0.24N/M vs Q3 2018 Operating Income-$7,192,000N/M Operating Cash Flowderived-$3,907,200N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
Free Cash Flowderived-$3,907,200N/M ended Dec 31, 2018 · filed Feb 12, 2019 · 43 d after period end